Maggie L. Shaw

An analysis of 30-year data on participants from the Augusta Heart study shows that Black individuals begin to exhibit potential signs of congestive heart failure earlier than their White counterparts.

Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.

Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.

A comparison of 2 time periods shows that following an initial decline, hospital admissions for primary management of heart failure rose between 2014 and 2017.

An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.

This year marks the 40th anniversary of the initial appearance in the United States of what we now know to be HIV and AIDS, first manifesting as Pneumocystis carinii pneumonia and Kaposi’s sarcoma among gay men and intravenous drug users.

Machine learning of data from 3 well-known heart studies shows a decline in heart failure risk from drinking at least 1 cup of caffeinated coffee each day.

Compared with a standard-protein diet, a high-protein diet reduced several markers of cardiometabolic risk in patients with heart failure and diabetes who were considered overweight or obese.

With New York being at the crossroads of the HIV epidemic and the coronavirus disease 2019 (COVID-19) pandemic, a group of researchers wanted to know what, if any, correlation there was between the 2 disease states.

An investigation of economic data from 3123 US counties, from 2007 to 2016, indicates that the cardiovascular mortality drop the authors saw may be a result of improved economic conditions.

Individuals with serious mental illness have a greater risk of acquiring HIV compared with the general population and could therefore benefit from preexposure prophylaxis (PrEP) services in the community.

The novel, first-in-class, small molecule prompted high rates of clinical response and molecular remission in patients with oligoblastic acute myeloid leukemia (AML).

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.

A 13.9% increase in diagnosed cases of HIV was seen following expansion of Medicaid coverage under the Affordable Care Act.

Higher mortality rates were seen among patients with acute lymphoblastic leukemia (ALL) who were considered obese, in a recent study of patients treated at Mayo Clinic.

Women receiving treatment for early-stage breast cancer may have a lower risk of developing heart failure if their therapy regimens include statins.

Despite outcome improvements for acute lymphoblastic leukemia (ALL), mortality rates remain high, with significant survival disparities seen between Black and White children.

Research findings from Mayo Clinic investigators demonstrate that diabetes did not increase the risk of death among patients with acute or chronic myeloid leukemia.

Both women and men have a greater chance of 90-day hospital readmission when they are considered to be in frail condition from heart failure.

Recipients of hematopoietic stem-cell transplantation (HSCT) who develop coronavirus disease 2019 (COVID-19) may be predisposed to a greater mortality rate if they meet certain disease criteria.

The 62nd American Society of Hematology (ASH) Annual Meeting and Exposition featured leading experts in hematology and covered some of the most cutting-edge research in the field.

Exciting new and ongoing developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 62nd American Society of Hematology (ASH) annual meeting.

Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.

Tyrosine kinase inhibitor (TKI) therapy enables patients with chronic myeloid leukemia (CML) to reach life expectancies equivalent to the general population and treatment-free remission, but quality of life can deteriorate with treatment.

A comparison of 3 levels of SARS-CoV-2 antibodies in convalescent plasma shows that the 30-day death rate was lowest in the group receiving high-titer plasma.

Use of the RNA inhibitor givosiran was shown to reduce expression of delta-aminolevulinic acid synthase 1, in turn reducing the severity of acute attacks and chronic symptoms for patients with severe hepatic porphyria.

A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.

The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.

A recent meta-analysis appearing in Journal of Cancer indicates a connection between minimal residual disease (MRD)–positive status and worse progression-free survival (PFS) and overall survival (OS) following induction and consolidation therapies.

Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).